TNKase (T-N-Kase, tenecteplase), a new thrombolytic for acute MIs

July 2000

Genentech is now introducing TNKase (T-N-Kase, tenecteplase), a new thrombolytic for acute MIs.

TNKase is a modified version of Activase (alteplase, tPA). It's made by substituting 3 amino acids of the tPA enzyme.

TNKase and Activase have comparable efficacy for restoring blood flow and improving survival after an MI.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

more aggressive treatment of hypertension in patients with diabetes
Allergic Reactions which drugs might cause problems in patients with sulfa allergies
Cardiology starting statins EARLIER after an MI
Cardiology TNKase (T-N-Kase, tenecteplase), a new thrombolytic for acute MIs
new guidelines for treating asthma during pregnancy
Women's Health lengthening oral contraceptive cycles
Women's Health low-dose oral contraceptives to women right up to menopause
Women's Health Activella, a new combo HRT tablet for postmenopausal women
Infectious Diseases new guidelines for treating latent tuberculosis
Cynara-SL, a new dietary supplement made from artichokes
Zyprexa (olanzapine) for treating acute mania in patients with bipolar disorder
Provigil (modafinil) helps reduce fatigue in patients with multiple sclerosis
Stroke aspirin should be started sooner for most stroke patients
Practice splendid review of our Natural Medicines Comprehensive Database